drugset / Trial / NCT06730750
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
Timeline
- Start
- 2025-02-12
- Primary completion
- 2026-09-05
- Completion
- 2029-12-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986490 | Unknown | — | — |
| Subject | Bevacizumab | Monoclonal antibody | — | — |